Ying-Jie Li1, Cong Dai2, Min Jiang3. 1. Department of Gastroenterology, First Affiliated Hospital, China Medical University, No. 92 of Beier Road, Heping District, Shenyang City, 110001, Liaoning Province, China. 2. Department of Gastroenterology, First Affiliated Hospital, China Medical University, No. 92 of Beier Road, Heping District, Shenyang City, 110001, Liaoning Province, China. congdai2006@sohu.com. 3. Department of Gastroenterology, First Affiliated Hospital, China Medical University, No. 92 of Beier Road, Heping District, Shenyang City, 110001, Liaoning Province, China. minjiangcmu@126.com.
Abstract
BACKGROUND: Mast cells (MCs), PAR2 and TRPV1, play a key role in the regulation of visceral pain. Several studies have found that probiotics regulate visceral sensitivity. AIMS: The purpose of the current study was to explore the role of MC-PAR2-TRPV1 in VH and the mechanism of VSL#3 in a rat model of VH. METHODS: A total of 64 rats were randomly divided into eight groups: Control VH, VH + ketotifen, VH + FSLLRY-NH2, VH + SB366791, VH + VSL#3, VH + VSL#3 + capsaicin, and VH + VSL#3 + SLIGRL-NH2. The rat model of VH was induced by acetic acid enema and the partial limb restraint method. VH was assessed by the abdominal withdrawal reflex score. MCs in colonic tissue were detected by the toluidine blue staining assay. The expression of PAR2 and TRPV1 in DRGs (L6-S1) was measured by immunohistochemistry and Western blotting. RESULTS: The established VH was abolished by treatment with ketotifen, a mast cell stabilizer FSLLRY-NH2, a PAR2 antagonist SB366791 a TRPV1 antagonist, and probiotic VSL#3 in rats. The administration of ketotifen or probiotic VSL#3 caused a decrease in mast cell number in the colon and decreased PAR2 and TRPV1 expression in DRGs. Intrathecal injection of FSLLRY-NH2 or SB366791 caused decreased expression of PAR2 and/or TRPV1 in DRGs in VH rats. SLIGRL-NH2, a PAR2 agonist, and capsaicin, a TRPV1 agonist, blocked the effects of probiotic VSL#3. CONCLUSIONS: The probiotic VSL#3 decreases VH in rat model of VH. The mechanism may be related with the mast cell-PAR2-TRPV1 signaling pathway.
BACKGROUND: Mast cells (MCs), PAR2 and TRPV1, play a key role in the regulation of visceral pain. Several studies have found that probiotics regulate visceral sensitivity. AIMS: The purpose of the current study was to explore the role of MC-PAR2-TRPV1 in VH and the mechanism of VSL#3 in a rat model of VH. METHODS: A total of 64 rats were randomly divided into eight groups: Control VH, VH + ketotifen, VH + FSLLRY-NH2, VH + SB366791, VH + VSL#3, VH + VSL#3 + capsaicin, and VH + VSL#3 + SLIGRL-NH2. The rat model of VH was induced by acetic acid enema and the partial limb restraint method. VH was assessed by the abdominal withdrawal reflex score. MCs in colonic tissue were detected by the toluidine blue staining assay. The expression of PAR2 and TRPV1 in DRGs (L6-S1) was measured by immunohistochemistry and Western blotting. RESULTS: The established VH was abolished by treatment with ketotifen, a mast cell stabilizer FSLLRY-NH2, a PAR2 antagonist SB366791 a TRPV1 antagonist, and probiotic VSL#3 in rats. The administration of ketotifen or probiotic VSL#3 caused a decrease in mast cell number in the colon and decreased PAR2 and TRPV1 expression in DRGs. Intrathecal injection of FSLLRY-NH2 or SB366791 caused decreased expression of PAR2 and/or TRPV1 in DRGs in VH rats. SLIGRL-NH2, a PAR2 agonist, and capsaicin, a TRPV1 agonist, blocked the effects of probiotic VSL#3. CONCLUSIONS: The probiotic VSL#3 decreases VH in rat model of VH. The mechanism may be related with the mast cell-PAR2-TRPV1 signaling pathway.
Authors: Silvia Amadesi; Graeme S Cottrell; Lorna Divino; Kevin Chapman; Eileen F Grady; Francisco Bautista; Rustum Karanjia; Carlos Barajas-Lopez; Stephen Vanner; Nathalie Vergnolle; Nigel W Bunnett Journal: J Physiol Date: 2006-06-22 Impact factor: 5.182
Authors: Mar Guilarte; Javier Santos; Inés de Torres; Carmen Alonso; María Vicario; Laura Ramos; Cristina Martínez; Francesc Casellas; Esteban Saperas; Juan Ramón Malagelada Journal: Gut Date: 2006-09-27 Impact factor: 23.059
Authors: F Azpiroz; M Bouin; M Camilleri; E A Mayer; P Poitras; J Serra; R C Spiller Journal: Neurogastroenterol Motil Date: 2007-01 Impact factor: 3.598
Authors: Kwai A Alier; Jaclyn A Endicott; Patrick L Stemkowski; Nicolas Cenac; Laurie Cellars; Kevin Chapman; Patricia Andrade-Gordon; Nathalie Vergnolle; Peter A Smith Journal: J Pharmacol Exp Ther Date: 2007-10-05 Impact factor: 4.030
Authors: H Liu; D V Miller; S Lourenssen; R W Wells; M G Blennerhassett; W G Paterson Journal: Neurogastroenterol Motil Date: 2009-09-09 Impact factor: 3.598
Authors: Laura López-Gómez; Jaime Antón; Yolanda López-Tofiño; Bianca Pomana; José A Uranga; Raquel Abalo Journal: Int J Environ Res Public Health Date: 2022-05-26 Impact factor: 4.614